首页> 美国政府科技报告 >Phosphoproteomic Assessment of Therapeutic Kinases for Personalized Therapy in Castration-Resistant Prostate Cancer.

【24h】

Phosphoproteomic Assessment of Therapeutic Kinases for Personalized Therapy in Castration-Resistant Prostate Cancer.

机译：抗去势的前列腺癌个性化治疗的治疗激酶的磷酸化蛋白质组学评估。

获取原文

页面导航

著录项
相似文献
相关主题

著录项

作者
Drake, J. M.;
展开▼
作者单位

展开▼
年度 2016
页码 1-56
总页数 56
原文格式 PDF
正文语种 eng
中图分类
关键词
Prostate cancer; Oncology; Metastasis; Mass spectrometry; Diagnostic imaging; Therapeutics; Phosphoproteomics; Metastatic; Castration resistant prostate cancer; Kinase;

机译：前列腺癌;肿瘤学;转移;质谱;诊断成像;治疗学;磷酸化蛋白质组学;转移;去势抵抗性前列腺癌;激酶;

相似文献

外文文献
中文文献
专利

1. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. [J] . Uemura H, Fujimoto K, Mine T, Cancer science. . 2010,第3期

机译：对去势抵抗性前列腺癌患者进行个性化肽疫苗单药治疗的免疫学评估。
2. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. [J] . Jing Li, Andrew J Armstrong Clinical advances in hematology & oncology: H&O . 2015,第5期

机译：要点：在有症状的转移性去势抵抗性前列腺癌，多西他赛或镭中应首先使用哪种？ Radium-223是以骨为主的症状性转移去势抵抗性前列腺癌的首选治疗方法。
3. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. [J] . Marc B Garnick BJU international . 2012,第8期

机译：编辑评论。对使用比卡鲁胺的联合雄激素阻断治疗的前列腺特异性抗原反应，可预测去势抵抗性前列腺癌患者随后接受雌激素和多西他赛治疗后的存活率。
4. In Vivo Small Animal Imaging for Early Assessment of Therapeutic Efficacy of Photodynamic Therapy for Prostate Cancer [C] . Baowei Fei, Hesheng Wang, Xiang Chen, Conference on Medical Imaging 2007: Physiology, Function, and Structure from Medical Images pt.1 . 2006

机译：体内小动物成像，早期评估光动力疗法治疗前列腺癌的疗效
5. Determination of novel metabolites of therapeutic agents used in the treatment of castration-resistant prostate cancer. [D] . Alyamani, Mohammad. 2017

机译：测定用于去势抵抗性前列腺癌的治疗剂的新代谢产物。
6. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis [O] . Finn Edler von Eyben, Glenn Bauman, Rie von Eyben, 2020

机译：优化对转移性阉割抗性前列腺癌患者的PSMA放射性配体疗法。系统审查和荟萃分析
7. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer [O] . Yoshimura Kazuhiro, Minami Takafumi, Nozawa Masahiro, 2016

机译：低剂量地塞米松与单独使用地塞米松的个体化肽疫苗免疫治疗的2期随机对照试验在未经化疗的未接受去势的前列腺癌中的应用

Phosphoproteomic Assessment of Therapeutic Kinases for Personalized Therapy in Castration-Resistant Prostate Cancer.

著录项

相似文献

相关主题

期刊订阅